

## Aviso de Derechos para emisoras del

FECHA: 16/01/2026



### BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:

<b>FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO</b>	280459
<b>FOLIO DE REFERENCIA INDEVAL</b>	877619C002
<b>TIPO DE MENSAJE</b>	Replace
<b>COMPLETO / INCOMPLETO</b>	COMPLETE
<b>CONFIRMADO / NO CONFIRMADO</b>	CONFIRMED

<b>CLAVE DE COTIZACIÓN</b>	AZN
<b>RAZÓN SOCIAL</b>	ASTRAZENECA GROUP PLC
<b>SERIE</b>	N
<b>ISIN</b>	US0463531089
<b>MERCADO PRINCIPAL</b>	NASDAQ

<b>TIPO DE EVENTO</b>	EXCHANGE
-----------------------	----------

<b>MANDATORIO / OPCIONAL / VOLUNTARIO</b>	Voluntary
---	-----------

<b>OPCIÓN</b>	999
<b>TIPO</b>	NoAction
<b>DEFAULT</b>	true

<b>NOTA</b>	
TAKE NO ACTION	

<b>OPCIÓN</b>	1
<b>TIPO</b>	Security
<b>DEFAULT</b>	false

**Aviso de Derechos para emisoras del**

FECHA: 16/01/2026

<b>MARKET DEADLINE</b>	27/01/2026
------------------------	------------

<b>TRANSACCIÓN</b>	Securities Movement
<b>CREDIT / DEBIT</b>	Debit

<b>VALORES A RECIBIR</b>	
	US0463531089

<b>TRANSACCIÓN</b>	Securities Movement
<b>CREDIT / DEBIT</b>	Credit

<b>RATIO</b>	NewToOld
	1 / 2
<b>VALORES A RECIBIR</b>	
	GB0009895292
<b>DISPOSICIÓN FRACCIONES</b>	CashInLieuOfFraction

<b>NOTA</b>
Holders may exchange their ADSs and receive the underlying shares.

<b>NOTAS DEL EVENTO CORPORATIVO</b>
-------------------------------------

<b>NOTA</b>
15/01/2026
<p>JPMorgan Chase Bank, N.A. has received notice from AstraZeneca PLC that at the general meeting held on November 3, 2025, AstraZeneca's shareholders approved the special resolution to amend the articles of association of the Company in order to facilitate what the Company has described as the harmonization of the Company's share listing structure by way of the direct listing of the Company's ordinary shares. J.P. Morgan has been informed by AstraZeneca that the Direct U.S. Listing on the NYSE is expected to become effective on February 2, 2026.</p> <p>AstraZeneca has further advised J.P. Morgan that, in connection with the implementation of the Harmonized Listing Structure, it is terminating the Second Amended and Restated Deposit Agreement dated as of February 6, 2025 by and among AstraZeneca, J.P. Morgan and all registered holders and beneficial owners from time to time of ADRs evidencing ADSs issued thereunder. All capitalized terms used, but not otherwise defined herein, shall have the meaning given to such terms in the Deposit Agreement.</p> <p>In accordance with the provisions of the Deposit Agreement, J.P. Morgan hereby notifies Holders that the Deposit Agreement is terminated effective at the open of business (New York time) on February 2, 2026. Please note that ADS issuance and cancellation books will be closed starting from close of business on January 27, 2026.</p> <p>AstraZeneca has requested that the Depositary notify Holders that (i) as a result of the implementation of the Harmonized Listing Structure and the termination of the Deposit Agreement, existing ADSs will be mandatorily cancelled at or around the Termination Time so that for every two ADSs a Holder has immediately prior to the Termination Time such Holder will be entitled to receive one AstraZeneca Share, (ii) where Cede &amp; Co. is the Holder, such AstraZeneca Shares will be distributed to Cede &amp; Co. by Computershare</p>

**Aviso de Derechos para emisoras del**

FECHA: 16/01/2026

Trust Company N.A., in its capacity as transfer agent, (iii) Computershare Trust Company, N.A., in its capacity as election agent, will reach out to all Holders other than Cede & Co. seeking instructions on how their interests in the Shares shall be held and (iv) for any Holder whose ADSs cannot be exchanged for a whole number of AstraZeneca Shares, such fractional entitlements will be aggregated and sold by the -/0 DR Market Announcement Transfer Agent with any net proceeds from the sale being allocated on a pro rata basis to such Holders. Neither J.P. Morgan nor any of its agents is involved in any of the actions described in this paragraph. Holders should contact the Company with any questions related thereto.

Holders are advised that AstraZeneca and J.P. Morgan have agreed that any and all cancellation fees payable to J.P. Morgan under the terms of the Deposit Agreement for the cancellation of the AstraZeneca ADRs held as of the ADR Termination Time will be paid by AstraZeneca.

Holders may contact the agent for cancellation of their shares.